Aditxt, Inc. is a biotech company. The Company is engaged in developing and commercializing technologies with a focus on monitoring and modulating the immune system. It is developing ADI products for organ transplantation, including skin allografting, autoimmune diseases and allergies, with the initial focus on psoriasis, type 1 diabetes and skin allografting, indications for which the Company has compelling preclinical data. The Company's portfolio includes two programs: Adimune and AditxtScore. Adimune program is engaged in immune modulation technologies, which are in the pre-clinical stage and are designed to retrain the immune system to induce tolerance with the objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. AditxtScore is engaged in immune monitoring technologies designed to provide a personalized, comprehensive profile of the immune system.
More about the company